Innate Pharma Sa SEC Filings

IPHA NASDAQ

Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Innate Pharma’s latest 10-K means navigating dense sections on NK cell biology, multi-partner milestone payments, and pages of trial data tables. If you’ve ever hunted for the cash runway figure or wondered which antibody just advanced to Phase 2, you know how time-consuming these biotech disclosures can be.

Stock Titan solves that problem. Our AI-powered summaries turn hundreds of pages into concise insights, so “Innate Pharma SEC filings explained simply” becomes reality. Get real-time alerts the moment an 8-K material event is filed, scan an “Innate Pharma quarterly earnings report 10-Q filing” for R&D spend, or track “Innate Pharma insider trading Form 4 transactions” with instant notifications. Need the big picture? Our platform links each note on collaboration revenue straight to the partner agreement disclosed in the exhibits, while flagging any dilution risk hidden in the footnotes.

Whether you’re monitoring “Innate Pharma executive stock transactions Form 4”, comparing trial milestones across quarters, or reviewing the proxy statement executive compensation package, Stock Titan keeps every filing type at your fingertips. Analysts rely on AI-highlighted sections that explain pivotal trial endpoints, cash-burn trends, and royalty structures. Investors use our side-by-side charts to benchmark pipeline progress, while compliance teams appreciate that every annual report 10-K is simplified without losing critical detail. From earnings report filing analysis to 8-K material events explained, understanding Innate Pharma’s SEC documents with AI has never been easier.

07/07/2025 06:03 AM

Filing

[6-K] Innate Pharma S.A. ADS Current Report (Foreign Issuer)

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Innate Pharma Sa (IPHA)?

The current stock price of Innate Pharma Sa (IPHA) is $1.72 as of July 9, 2025.

What is the market cap of Innate Pharma Sa (IPHA)?

The market cap of Innate Pharma Sa (IPHA) is approximately 170.0M.

What is Innate Pharma SA's core business?

Innate Pharma SA is focused on developing innovative immunotherapies that harness the innate immune system to improve cancer treatment outcomes using therapeutic antibodies.

How does the company generate revenue?

Revenue is primarily generated through research collaboration agreements, licensing deals, and strategic partnerships with established biopharmaceutical companies.

What distinguishes Innate Pharma SA’s approach to cancer treatment?

The company leverages its deep expertise in natural killer cell biology and innovative antibody platforms to develop therapies that mobilize the innate immune system against cancer cells.

How diversified is the company’s clinical pipeline?

Innate Pharma SA has built a diversified pipeline including first-in-class clinical stage antibodies and preclinical candidates designed to target a broad range of cancer indications.

What role do strategic collaborations play in the company’s operations?

Strategic collaborations with major biopharmaceutical companies provide validation for its scientific innovations while supporting accelerated clinical development and expanding research capabilities.

How does Innate Pharma SA differentiate itself from competitors?

Its unique focus on leveraging the innate immune system, combined with proprietary therapeutic platforms and a strong pipeline of innovative antibodies, sets it apart in the competitive immuno-oncology space.